$5.3 Billion Deal: Should Mylan Stock Investors Cheer or Jeer?

Mylan just signed a huge deal with Abbott Labs -- was it a good or a bad move?

Michael Douglass
Michael Douglass and Dave Williamson
Jul 14, 2014 at 6:13PM
Health Care

Abbott Labs (NYSE:ABT) and Mylan (NASDAQ:MYL) gave investors reason to cheer today. Mylan bought up Abbott's established pharmaceuticals portfolio in non-emerging, ex-U.S. markets for $5.3 billion in an all-stock deal.

Was it a good idea for Mylan shareholders?

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.